Business Context and Reporting Period
Company: Biorestorative Therapies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 5, 2021
Context: The filing serves as a Regulation FD disclosure to distribute a press release and a letter to shareholders regarding the Company and its business. The Company is identified as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a press release rather than a financial statement.
Material Changes
No material financial changes or comparative period data are disclosed within the text of this Form 8-K. The document references a press release (Exhibit 99.1) for details on the Company's business status but does not summarize those details in the main body.
Guidance, Outlook, and Risks
- Management Commentary: The Company issued a press release and a letter to shareholders on January 5, 2021, which are incorporated by reference as Exhibit 99.1.
- Forward-Looking Statements: The Company explicitly disclaims any obligation to update the information contained in the press release or to reflect events occurring after the date of this report.
- Legal Status: The information is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, limiting liability exposure.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated January 5, 2021) for the actual content of the shareholder letter and business updates.
- Verify the Company's status as an emerging growth company and its implications for financial reporting standards.
- Check the Investors & Media section of the Company's website (www.biorestorative.com) for the press release, as noted in the filing.
- Confirm that no specific financial figures are present in this 8-K and refer to the most recent 10-K or 10-Q for quantitative data.